Literature DB >> 27094588

Left-sided breast cancer loco-regional radiotherapy with deep inspiration breath-hold: Does volumetric-modulated arc radiotherapy reduce heart dose further compared with tangential intensity-modulated radiotherapy?

Trang T Pham1,2, Rachel Ward1, Drew Latty1, Catherine Owen1, Val Gebski1,3, Jacek Chojnowski1, Christopher Kelly1, Verity Ahern1,2,4, Kenneth Tiver1,2, Kirsty Stuart1,2, Wei Wang1,2,4.   

Abstract

INTRODUCTION: Left-sided breast cancer radiotherapy has been associated with an increase in cardiac mortality. This study investigated the potential heart-sparing effect of volumetric-modulated arc radiotherapy (VMAT). We compared VMAT to tangential intensity-modulated radiotherapy (t-IMRT) in the loco-regional treatment of left-sided breast cancer, including internal mammary nodal irradiation, based on deep inspiration breath-hold (DIBH) and free-breathing (FB).
METHODS: Radiotherapy for 15 patients was re-planned. Four plans were compared: t-IMRT-DIBH; VMAT-DIBH; t-IMRT-FB; VMAT-FB. Prescribed dose was 50 Gy in 25 fractions. T-IMRT plans were generated using tangentially orientated fields. VMAT plans were generated using two partial arcs (average arc 190°).
RESULTS: Mean heart dose (MHD) was 5 ± 2.4 Gy, 5.7 ± 1.4 Gy, 9.7 ± 3.3 Gy and 8.1 ± 2.0 Gy for t-IMRT-DIBH, VMAT-DIBH, IMRT-FB and VMAT-FB respectively. The difference in MHD between IMRT-DIBH and VMAT-DIBH was not significant (P = 0.14). VMAT-DIBH significantly spared the volume of heart irradiated to doses of 20 Gy and above (p < 0.05), however, resulted in a significantly higher V5 Gy (P < 0.001), compared to t-IMRT-DIBH. VMAT-DIBH resulted in higher combined lung mean (11 ± 0.8 Gy vs. 8.8 ± 1.1 Gy, P < 0.001) and higher contralateral breast mean dose (5 ± 1 Gy vs. 1.6 ± 1.2 Gy, P < 0.001) compared with t-IMRT-DIBH.
CONCLUSIONS: On average, there was no significant difference in MHD between VMAT-DIBH and t-IMRT-DIBH. However, VMAT-DIBH was found to benefit a select group of patients. For patients in whom the MHD was >6.3 Gy with t-IMRT-DIBH, the use of VMAT-DIBH resulted in a benefit in reducing the MHD.
© 2016 The Royal Australian and New Zealand College of Radiologists.

Entities:  

Keywords:  IMRT; VMAT; breast cancer; breath-hold; cardiac toxicity

Mesh:

Year:  2016        PMID: 27094588     DOI: 10.1111/1754-9485.12459

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  18 in total

1.  Safety and benefit of using a virtual bolus during treatment planning for breast cancer treated with arc therapy.

Authors:  Marguerite Tyran; Agnes Tallet; Michel Resbeut; Marjorie Ferre; Veronique Favrel; Pierre Fau; Laurence Moureau-Zabotto; Julien Darreon; Laurence Gonzague; Ahcene Benkemouche; Leonel Varela-Cagetti; Naji Salem; Bertrand Farnault; Marie-Aimee Acquaviva; Hugues Mailleux
Journal:  J Appl Clin Med Phys       Date:  2018-06-30       Impact factor: 2.102

2.  Reduction of cardiac and coronary artery doses in irradiation of left-sided breast cancer during inspiration breath hold : A planning study.

Authors:  S Schönecker; C Heinz; M Söhn; W Haimerl; S Corradini; M Pazos; C Belka; H Scheithauer
Journal:  Strahlenther Onkol       Date:  2016-09-08       Impact factor: 3.621

3.  Left-sided breast cancer and risks of secondary lung cancer and ischemic heart disease : Effects of modern radiotherapy techniques.

Authors:  Stefanie Corradini; Hendrik Ballhausen; Helmut Weingandt; Philipp Freislederer; Stephan Schönecker; Maximilian Niyazi; Cristoforo Simonetto; Markus Eidemüller; Ute Ganswindt; Claus Belka
Journal:  Strahlenther Onkol       Date:  2017-09-15       Impact factor: 3.621

4.  Cardiac Function after Modern Radiation Therapy with Volumetric Modulated Arc Therapy or Helical Tomotherapy for Advanced Left-Breast Cancer Receiving Regional Nodal Irradiation.

Authors:  Pei-Yu Hou; Chen-Hsi Hsieh; Le-Jung Wu; Chen-Xiong Hsu; Deng-Yu Kuo; Yueh-Feng Lu; Yen-Wen Wu; Hui-Ju Tien; Shih-Ming Hsu; Pei-Wei Shueng
Journal:  Bioengineering (Basel)       Date:  2022-05-16

Review 5.  Critical appraisal of the role of volumetric modulated arc therapy in the radiation therapy management of breast cancer.

Authors:  Luca Cozzi; Frank Lohr; Antonella Fogliata; Davide Franceschini; Fiorenza De Rose; A R Filippi; Gabriele Guidi; Valentina Vanoni; Marta Scorsetti
Journal:  Radiat Oncol       Date:  2017-12-19       Impact factor: 3.481

6.  Radiation dose to the left anterior descending coronary artery during interstitial pulsed-dose-rate brachytherapy used as a boost in breast cancer patients undergoing organ-sparing treatment.

Authors:  Marcin Sinacki; Krystyna Serkies; Rafał Dziadziuszko; Magdalena Narkowicz; Joanna Kamińska; Joanna Lipniewicz
Journal:  J Contemp Brachytherapy       Date:  2017-02-15

7.  Dosimetric analysis of tangent-based volumetric modulated arc therapy with deep inspiration breath-hold technique for left breast cancer patients.

Authors:  Pei-Chieh Yu; Ching-Jung Wu; Yu-Lun Tsai; Suzun Shaw; Shih-Yu Sung; Louis Tak Lui; Hsin-Hua Nien
Journal:  Radiat Oncol       Date:  2018-11-26       Impact factor: 3.481

8.  Evaluation of abches and volumetric modulated arc therapy under deep inspiration breath-hold technique for patients with left-sided breast cancer: A retrospective observational study.

Authors:  Tien-Chi Yeh; Mau-Shin Chi; Kwan-Hwa Chi; Chung-Hsien Hsu
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

9.  Tangent-based volumetric modulated arc therapy for advanced left breast cancer.

Authors:  Pei-Chieh Yu; Ching-Jung Wu; Hsin-Hua Nien; Louis Tak Lui; Suzun Shaw; Yu-Lun Tsai
Journal:  Radiat Oncol       Date:  2018-11-28       Impact factor: 3.481

10.  Reduction in low-dose to normal tissue with the addition of deep inspiration breath hold (DIBH) to volumetric modulated arc therapy (VMAT) in breast cancer patients with implant reconstruction receiving regional nodal irradiation.

Authors:  Vishruta A Dumane; Kitwadee Saksornchai; Ying Zhou; Linda Hong; Simon Powell; Alice Y Ho
Journal:  Radiat Oncol       Date:  2018-09-24       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.